Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis

References

• Gilhar A, Laufer-Britva R, Keren A, et al. Frontiers in alopecia areata pathobiology research. J Allergy Clin Immunol. 2019;144(6):1478–1489.
   PubMed Web of Science ®Google Scholar
• McKenzie PL, Maltenfort M, Bruckner AL, et al. Evaluation of the prevalence and incidence of pediatric alopecia areata using electronic health record data. JAMA Dermatol. 2022;158(5):547–551.
   PubMed Web of Science ®Google Scholar
• Hamilton CE, Craiglow BG. JAK inhibitors for the treatment of pediatric alopecia areata. J Investig Dermatol Symp Proc. 2020;20(1):S31–S36.
   PubMedGoogle Scholar
• Mukherjee N, Burkhart CN, Morrell DS. Treatment of alopecia areata in children. Pediatr Ann. 2009;38(7):388–395.
   PubMed Web of Science ®Google Scholar
• Peloquin L, Castelo-Soccio L. Alopecia areata: an update on treatment options for children. Paediatr Drugs. 2017;19(5):411–422.
   PubMed Web of Science ®Google Scholar
• Toussi A, Barton VR, Le ST, et al. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162–175.
   PubMed Web of Science ®Google Scholar
• Sonthalia S, Aggarwal P. Oral tofacitinib: contemporary appraisal of its role in dermatology. Indian Dermatol Online J. 2019;10(5):503–518.
   PubMedGoogle Scholar
• Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016;28(4):463–469.
   PubMed Web of Science ®Google Scholar
• Park KS. Pharmacological effects of Centella asiatica on skin diseases: evidence and possible mechanisms. Evid Based Complement Alternat Med. 2021;2021:5462633.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. 2016;152(4):490–491.
   PubMed Web of Science ®Google Scholar
• Sawyer SM, Azzopardi PS, Wickremarathne D, et al. The age of adolescence. Lancet Child Adolesc Health. 2018;2(3):223–228.
   PubMedGoogle Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29–32.
   PubMed Web of Science ®Google Scholar
• Bayart CB, DeNiro KL, Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–170.
   PubMed Web of Science ®Google Scholar
• Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol. 2017;76(4):754–755.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol. 2019;80(2):568–570.
   PubMed Web of Science ®Google Scholar
• Dai Y-X, Chen C-C. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol. 2019;80(4):1164–1166.
   PubMed Web of Science ®Google Scholar
• Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study. Pediatr Dermatol. 2021;38(1):103–108.
   PubMed Web of Science ®Google Scholar
• Kibbie J, Kines K, Norris D, et al. Oral tofacitinib for the treatment of alopecia areata in pediatric patients. Pediatr Dermatol. 2022;39(1):31–34.
   PubMed Web of Science ®Google Scholar
• Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566–568.
   PubMed Web of Science ®Google Scholar
• Morales-Miranda AY, Bueno-Arias GM, Aguirre-Félix ÓG, et al. Tofacitinib as a treatment of alopecia areata in adolescents. Bol Med Hosp Infant Mex. 2019;76(4):182–187.
   PubMed Web of Science ®Google Scholar
• Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol. 2018;78(6):1207–1209.e1.
   PubMed Web of Science ®Google Scholar
• Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.
   PubMed Web of Science ®Google Scholar
• Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113–117.
   PubMed Web of Science ®Google Scholar
• Goh C, Finkel M, Christos PJ, et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venerol. 2006;20(9):1055–1060.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984–1996.
   PubMed Web of Science ®Google Scholar
• AlMutairi N, Nour T. Tofacitinib in pediatric psoriasis: an open-label trial to study its safety and efficacy in children. Dermatology. 2020;236(3):191–198.
   PubMed Web of Science ®Google Scholar
• King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–1699.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837–852.
   PubMed Web of Science ®Google Scholar
• Yu D-A, Kim YE, Kwon O, et al. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2021;87(5):621–627.
   PubMed Web of Science ®Google Scholar
• Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–856.
   PubMed Web of Science ®Google Scholar